Treatment of advanced head and neck carcinoma with synchronous irradiation and methotrexate

Thirty-four patients with advanced head and neck cancer were treated by synchronous radiotherapy and methotrexate (MTX) (100 mg/m2). Complete resolution of disease was obtained in 18 patients, the median remission of patients being 17 months. In general, treatment was well tolerated, although mucosa...

Full description

Saved in:

Bibliographic Details
Published in:	Cancer treatment reports Vol. 65 Suppl 1; p. 145
Main Authors:	Pointon, R C, Askill, C S, Hunter, R D, Wilkinson, P M
Format:	Journal Article
Language:	English
Published:	United States 1981
Subjects:	Blood Cell Count - drug effects Blood Cell Count - radiation effects Carcinoma, Squamous Cell - drug therapy Carcinoma, Squamous Cell - pathology Carcinoma, Squamous Cell - radiotherapy Drug Administration Schedule Female Head and Neck Neoplasms - drug therapy Head and Neck Neoplasms - pathology Head and Neck Neoplasms - radiotherapy Humans Male Methotrexate - adverse effects Methotrexate - therapeutic use Middle Aged Mucous Membrane - drug effects Mucous Membrane - radiation effects Neoplasm Staging Pilot Projects Prognosis Radiotherapy - adverse effects
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Thirty-four patients with advanced head and neck cancer were treated by synchronous radiotherapy and methotrexate (MTX) (100 mg/m2). Complete resolution of disease was obtained in 18 patients, the median remission of patients being 17 months. In general, treatment was well tolerated, although mucosal reaction was prolonged in 50% of patients. Drug-induced hematological toxicity was observed in six patients (18%) and one patient died. As a result of these findings, a random clinical trial to compare X-ray therapy with X-ray therapy and MTX in advanced head and neck cancer has been commenced.
ISSN:	0361-5960